Skip to main content
SpringerLink
Log in

Pharmacogenomics and Phytochemicals

  • Chapter
  • First Online:
Cancer Genetics and Therapeutics

  • 543 Accesses

Abstract

It is well known for a long time that the same drugs have different efficacy in different patients due to variations in metabolism of the drugs. One of the reasons for these variations is the differences in genetic makeup of individuals. There may be variations in key inherited genes through germline cells from parents due to differences in copy numbers, variations due to single nucleotide polymorphism, or presence of different alleles of the same gene. There may also be variations in genetic makeup of somatic cells due to mutations in diseases like cancer. It is important to personalize medicines considering these genetic variations in individuals in order to decide on appropriate dosage for better outcome in treatment and also to reduce side effects of drugs. We have discussed the details of pharmacogenomics both due to genetic variations in germline cells and somatic cells. In particular we have discussed the effects of such genetic variations in cancer and how phytochemicals can mitigate the effects of some of these variations in cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. J. Baillargeon, H. Holmes, Y. Lin, M.A. Raji, G. Sharma, Y.F. Kuo, Concurrent use of warfarin and antibiotics and the risk of bleeding in older adults. Am. J. Med. 125(2), 183–189 (2012)

    Article  CAS  Google Scholar 

  2. S. Bak, F. Beisson, G. Bishop, B. Hamberger, R. Höfer, S. Paquette, D. Werck-Reichhart, Cytochromes p450. Arabidopsis Book. 9, e0144 (2011)

    Article  Google Scholar 

  3. P. Chatterjee, M.R. Franklin, Human cytochrome p450 inhibition and metabolic-intermediate complex formation by goldenseal extract and its methylenedioxyphenyl components. Drug Metab. Dispos. 31(11), 1391–1397 (2003)

    Article  CAS  Google Scholar 

  4. M.A. Correia, P.R. Sinclair, F. De Matteis, Cytochrome P450 regulation: The interplay between its heme and apoprotein moieties in synthesis, assembly, repair, and disposal. Drug Metab. Rev. 43(1), 1–26 (2010)

    Article  Google Scholar 

  5. M.F. Crader, J.K. Arnold, Warfarin drug interactions. [Updated 2019 Jan 17], in StatPearls [Internet], (Treasure Island, StatPearls Publishing, 2012).; 2019 Jan–. Available from: https://www.ncbi.nlm.nih.gov/books/NBK441964/

    Google Scholar 

  6. A.K. Daly, Pharmacogenetics: A general review on progress to date. Br. Med. Bull. 124, 65–79 (2017)

    CAS  PubMed  Google Scholar 

  7. L. Dean, Warfarin therapy and the genotypes CYP2C9 and VKORC1, medical genetics summaries, in Medical Genetics Summaries [Internet], ed. by V. Pratt, H. McLeod, L. Dean, et al., (National Center for Biotechnology Information (US), Bethesda, 2012)

    Google Scholar 

  8. T. Efferth, S. Kahl, K. Paulus, M. Adams, R. Rauh, H. Boechzelt, X. Hao, B. KAina, R. Bauer, Phytochemistry and pharmacogenomics of natural products derived from traditional Chinese medicine and chinese materia medica with activity against tumor cells. Mol. Cancer Ther. 7(1), 152 (2008)

    Article  CAS  Google Scholar 

  9. T. Efferth, M. Saeed, E. Mirghani, A. Alim, Z. Yassin, E. Saeed, H.E. Khalid, S. Daak, Integration of phytochemicals and phytotherapy into cancer precision medicine. Oncotarget 8(30), 50284–50304 (2017)

    Article  Google Scholar 

  10. R. Fagard, V. Metelev, I. Souissi, F. Baran-Marszak, STAT3 inhibitors for cancer therapy: Have all roads been explored? JAKSTAT 2(1), e22882 (2013)

    PubMed  PubMed Central  Google Scholar 

  11. K. Fujita, Y. Sasaki, Pharmacogenomics in drug-metabolizing enzymes catalyzing anticancer drugs for personalized cancer chemotherapy. Curr. Drug Metab. 8(6), 554–562 (2007)

    Article  CAS  Google Scholar 

  12. K. Fujita, Y. Kubota, H. Ishida, Y. Sasaki, Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer. World J. Gastroenterol. 21(43), 12234–12248 (2015)

    Article  CAS  Google Scholar 

  13. K.M. Giakomini, C.M. Brett, R.B. Altman, N.L. Benowitz, M.E. Dolan, D.A. Flockhart, J.A. Johnson, D.F. Hayes, T. Klein, R.M. Krauss, D.L. Kroetz, H.L. McLeod, A.T. Nguyen, M.J. Ratain, M.V. Relling, V. Reus, D.M. Roden, C.A. Schaefer, A.R. Shuldiner, T. Skaar, K. Tantisira, R.F. Tyndale, L. Wang, R.M. Weinshilboum, S.T. Weiss, I. Zineh, The Pharmacogenetics research network: From SNP discovery to clinical drug response. Clin. Pharmacol. Ther. 81(3), 328–345 (2007)

    Article  Google Scholar 

  14. F.J. Gonzalez, H.V. Gelboin, Human cytochromes P450: Evolution and cDNA-directed expression. Environ. Health Perspect. 98, 81–85 (1992)

    Article  CAS  Google Scholar 

  15. D. Gurwitz, M.M. Hopkins, S. Gaisser, D. Ibarreta, Pharmacogenetics in Europe: Barriers and opportunities. Public Health Genomics 12, 134–141 (2009)

    Article  CAS  Google Scholar 

  16. O. Hankinson, The aryl hydrocarbon receptor complex. Annu. Rev. Pharmacol. Toxicol. 35, 307–340 (1995)

    Article  CAS  Google Scholar 

  17. I. Hanukoglu, Electron transfer proteins of cytochrome P450 systems. Physiological functions of cytochrome P450 in relation to structure and regulation. Adv. Mol. Cell Biol. 14, 29–56 (1996)

    Article  CAS  Google Scholar 

  18. J.A. Hasler, R. Estabrook, M. Murray, I. Pikuleva, M. Waterman, J. Capdevila, V. Holla, C. Helvig, J.R. Falck, G. Farrell, L.S. Kaminsky, S.D. Spivack, E. Boitier, P. Beaune, Human cytochromes P450. Mol. Asp. Med. 20(1–2), 1–137 (1999)

    Article  CAS  Google Scholar 

  19. D.M. Hyman, B.S. Taylor, J. Baselga, Implementing genome-driven oncology. Cell 168(4), 584–599 (2017)

    Article  CAS  Google Scholar 

  20. M. Ingelman-Sundberg, C. Rodriguez-Antona, Pharmacogenetics of drug-metabolizing enzymes: Implications for a safer and more effective drug therapy. Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci. 360(1460), 1563–1570 (2005)

    Article  CAS  Google Scholar 

  21. M. Ingelman-Sundberg, Pharmacogenetics of cytochrome P450 and its applications in drug therapy: The past, present and future. Trends Pharmacol. Sci. 25(4), 193–200 (2004)

    Article  CAS  Google Scholar 

  22. C. Kearon, E.A. Akl, A.J. Comerota, P. Prandoni, H. Bounameaux, S.Z. Goldhaber, M.E. Nelson, P.S. Wells, M.K. Gould, F. Dentali, M. Crowther, S.R. Kahn, Antithrombotic therapy for VTE disease: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl), e419S–e496S (2012)

    Article  CAS  Google Scholar 

  23. D. Lee, C. Szumlanski, J. Houtman, R. Honchel, K. Rojas, J. Overhauser, E.D. Wieben, R.M. Weinshilboum, Thiopurine methyltransferase pharmacogenetics. Cloning of human liver cDNA and a processed pseudogene on human chromosome 18q21.1. Drug Metab. Dispos. 23(3), 398–405 (1995)

    CAS  PubMed  Google Scholar 

  24. W. Lee, A.C. Lockhart, R.B. Kim, M.L. Rothenberg, Cancer pharmacogenomics: Powerful tools in cancer chemotherapy and drug development. Oncologist 10, 104–111 (2005)

    Article  CAS  Google Scholar 

  25. X. Li, F.M. Lian, D. Guo, L. Fan, J. Tang, J.-B. Peng, H.-W. Deng, Z.-Q. Liu, X. Xiao, Y. Wang, K. Qu, S. Deng, Q. Zhong, Y. Sha, Y. Zhu, Y. Bai, X. Chen, Q. Zhou, H. Zhou, X. Tong, W. Zhang, The rs1142345 in TPMT affects the therapeutic effect of traditional hypoglycemic herbs in Prediabetes. Evid. Based Complement. Alternat. Med. 2013, 327629 (2013). 8 pages

    PubMed  PubMed Central  Google Scholar 

  26. N.A. Limdi, D.L. Veenstra, Warfarin Pharmacogenetics. Pharmacotherapy 28(9), 1084–1097 (2008)

    Article  CAS  Google Scholar 

  27. M.Z. Liu, Y.L. Zhang, M.Z. Zeng, F.Z. He, Z.Y. Luo, J.Q. Luo, J.G. Wen, X.P. Chen, H.H. Zhou, W. Zhang, Pharmacogenomics and herb-drug interactions: Merge of future and tradition. Evid. Based Complement. Alternat. Med. 2015, 321091 (2015). 8 pages

    PubMed  PubMed Central  Google Scholar 

  28. D.Y. Lu, T.R. Lu, B. Xu, J. Ding, Pharmacogenetics of cancer therapy: Breakthroughs from beyond? Future Sci. OA 1(4), FSO80 (2015)

    Article  Google Scholar 

  29. M.H. Manjili, Therapeutic cancer vaccines. J. Clin. Cell Immunol. 2, e101 (2011)

    Article  Google Scholar 

  30. M.C. McFadyen, W.T. Melvin, G.I. Murray, Cytochrome P450 enzymes: Novel options for cancer therapeutics. Mol. Cancer Ther. 3, 363–371 (2004)

    CAS  PubMed  Google Scholar 

  31. R. Nagasubramanian, F. Innocenti, M.J. Ratain, Pharmacogenetics in cancer treatment review of medicine. Annu. Rev. Med. 54(1), 437–452 (2003)

    Article  CAS  Google Scholar 

  32. D.W. Nebert, D.W. Russell, Clinical importance of the cytochromes P450. Lancet 360(9340), 1155–1162 (2002)

    Article  CAS  Google Scholar 

  33. H. Omote, M.K. Al-Shawi, Interaction of transported drugs with the lipid bilayer and P-glycoprotein through a solvation exchange mechanism. Biophys. J. 90(11), 4046–4059 (2006)

    Article  CAS  Google Scholar 

  34. R.P. Owen, L. Gong, H. Sagreiya, T.E. Klein, R.B. Altman, VKORC1 pharmacogenomics summary. Pharmacogenet. Genomics 20(10), 642–644 (2010)

    Article  CAS  Google Scholar 

  35. R.P. Owen, K. Sangkuhl, T.E. Klein, R.B. Altman, Cytochrome P450 2D6. Pharmacogenet. Genomics 19(7), 559–562 (2009)

    Article  CAS  Google Scholar 

  36. T. Oyama, N. Kagawa, N. Kunugita, K. Kitagawa, M. Ogawa, T. Yamaguchi, R. Suzuki, T. Kinaga, Y. Yashima, S. Ozaki, T. Isse, Y.D. Kim, H. Kim, T. Kawamoto, Expression of cytochrome P450 in tumor tissues and its association with cancer development. Front. Biosci. 9, 1967–1976 (2004)

    Article  CAS  Google Scholar 

  37. S.C. Preissner, M.F. Hoffmann, R. Preissner, M. Dunkel, A. Gewiess, S. Preissner, Polymorphic cytochrome P450 enzymes (CYPs) and their role in personalized therapy. PLoS One 8(12), e82562 (2013)

    Article  Google Scholar 

  38. M. Rooseboom, J.N. Commandeur, N.P. Vermeulen, Enzyme-catalyzed activation of anticancer prodrugs. Pharmacol. Rev. 56(1), 53–102 (2004)

    Article  CAS  Google Scholar 

  39. R.I. Shorr, W.A. Ray, J.R. Daugherty, M.R. Griffin, Concurrent use of non-steroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at risk for hemorrhagic peptic ulcer disease. Arch. Intern. Med. 153, 1665–1670 (1993)

    Article  CAS  Google Scholar 

  40. S.-H. Yang, C.-L. Yu, H.-Y. Chen, Y.-H. Lin, A commonly used Chinese herbal formula, Shu-Jing-Hwo-Shiee-Tang, potentiates anticoagulant activity of warfarin in a rabbit model. Molecules 18, 11712–11723 (2013)

    Article  CAS  Google Scholar 

  41. S.C. Sim, C. Risinger, M.L. Dahl, E. Aklillu, M. Christensen, L. Bertilsson, M. Ingelman-Sundberg, A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin. Pharmacol. Ther. 79, 103–113 (2006)

    Article  CAS  Google Scholar 

  42. C.Y. Tan, R. Suzuki, T. Haga, F. Iwata, T. Nagamune, Immobilization of a bacterial cytochrome P450 Monooxygenase system on a solid support. Angew. Chem. Int. Ed. 55(48), 15002–15006 (2016)

    Article  CAS  Google Scholar 

  43. N.E. Thomford, K. Dzobo, D. Chopera, A. Wonkam, M. Skelton, D. Blackhurst, S. Chirikure, C. Dandara, Pharmacogenomics implications of using herbal medicinal plants on African populations in health transition. Pharmaceuticals 8, 637–663 (2015)

    Article  CAS  Google Scholar 

  44. N. Toomula, K. Hima Bindu, D. Sathish Kumar, R. Arun Kumar, Pharmacogenomics- personalized treatment of Cancer, diabetes and cardiovascular diseases. J Pharmacogenom Pharmacoproteomics 3, 1 (2012)

    Article  Google Scholar 

  45. D. Urbančiča, A. Kotar, A. Šmid, M. Jukič, S. Gobec, L.G. Mårtensson, J. Plavec, I. Mlinarič-Raščan, Methylation of selenocysteine catalysed by thiopurine S-methyltransferase. Biochim. Biophys. Acta 1863(1), 182–190 (2019)

    Article  Google Scholar 

  46. M.M. Valenzuela, J.W. Neidigh, N.R. Wall, Antimetabolite treatment for pancreatic cancer. Chemotherapy (Los Angel). 3(3), 137 (2014)

    PubMed  PubMed Central  Google Scholar 

  47. H.A. Weber, M.K. Zart, A.E. Hodges, H.M. Molloy, B.M. O’Brien, L.A. Moody, A.P. Clark, R.K. Harris, J.D. Overstreet, C.S. Smith, Chemical comparison of goldenseal (Hydrastis canadensis L.) root powder from three commercial suppliers. J. Agric. Food Chem. 51(25), 7352–7358 (2003)

    Article  CAS  Google Scholar 

  48. M.T. Whitstock, C.M. Pearce, E.J. Eckermann, Randomised controlled trials and ‘unexpected’ adverse events associated with newly released drugs: Improvements in Pharmacovigilance systems are necessary for real-time identification of patient safety risks. J. Clin. Toxicol. S2, 001 (2011)

    Google Scholar 

  49. A.L. Wong, J. Hirpara, S. Pervaiz, J.-Q. Eu, G. Sethi, B.C. Goh, Do STAT3 inhibitors have potential in the future for cancer therapy? Expert Opin. Investig. Drugs 26(8), 883–887 (2017)

    Article  CAS  Google Scholar 

  50. A.L. Wong, R.A. Soo, D.S. Tan, S.C. Lee, J.S. Lim, P.C. Marban, L.R. Kong, Y.J. Lee, L.Z. Wang, W.L. Thuya, R. Soong, M.Q. Yee, T.M. Chin, M.T. Cordero, B.R. Asuncion, B. Pang, S. Pervaiz, J.L. Hirpara, A. Sinha, W.W. Xu, M. Yuasa, T. Tsunoda, M. Motoyama, T. Yamauchi, B.C. Goh, Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies. Ann. Oncol. 26, 998–1005 (2015)

    Article  CAS  Google Scholar 

  51. M. Yamamura, M. Yamamoto, Tumor metastasis and the fibrinolytic system. Gan to Kagaku Ryoho. Cancer Chemother. 16(4 Pt 2–1), 1246–1254 (1989)

    CAS  Google Scholar 

  52. B. Yu, S.A. O’Toole, R.J. Trent, Somatic DNA mutation analysis in targeted therapy of solid tumors. Translat. Pediatr. 4(2), 125–138 (2015)

    Google Scholar 

  53. H.Y. Yuan, J.J. Chen, M.T. Lee, J.C. Wung, Y.F. Chen, M.J. Charng, M.J. Lu, C.R. Hung, C.Y. Wei, C.H. Chen, J.Y. Wu, Y.T. Chen, A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum. Mol. Genet. 14(13), 1745–1751 (2005)

    Article  CAS  Google Scholar 

  54. U.M. Zanger, M. Schwab, Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol. Ther. 138, 103–141 (2013)

    Article  CAS  Google Scholar 

  55. G. Zaza, M. Cheok, W. Yang, J.C. Panetta, C.-H. Pui, M. Relling, W.E. Evans, Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment. Blood 106, 1778–1785 (2005)

    Article  CAS  Google Scholar 

  56. K. Zeratsky, Grapefruit juice: Can it cause drug interactions? Ask a food & nutrition specialist. MayoClinic.com. Retrieved 2009-02-09 (2008)

Download references

Author information

Authors and Affiliations

  1. Environmental Carcinogenesis and Toxicology, Chittaranjan National Cancer Institute, Kolkata, India

    Madhumita Roy

  2. Department of Computer Science and Software Engineering, The University of Western Australia, Perth, WA, Australia

    Amitava Datta

Authors
  1. Madhumita Roy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Amitava Datta
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Roy, M., Datta, A. (2019). Pharmacogenomics and Phytochemicals. In: Cancer Genetics and Therapeutics. Springer, Singapore. https://doi.org/10.1007/978-981-13-9471-3_7

Download citation

Publish with us

Policies and ethics

Search

Navigation